Aart A van Apeldoorn
Overview
Explore the profile of Aart A van Apeldoorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Bont D, Mohammed S, de Vries R, Paulino da Silva Filho O, Vaithilingam V, Jetten M, et al.
PLoS One
. 2025 Mar;
20(3):e0298114.
PMID: 40073008
Type 1 diabetic (T1D) patients are life-long dependent on insulin therapy to keep their blood glucose levels under control. An alternative cell-based therapy for exogenous insulin injections is clinical islet...
2.
Tol M, de Vries R, Engelse M, Carlotti F, van Apeldoorn A, de Koning E, et al.
Surg Innov
. 2024 Dec;
:15533506241306491.
PMID: 39670992
Background: Intraportal pancreatic islet transplantation is a treatment option for patients with severe beta cell failure and unstable glycemic control. However, this procedure is associated with loss of beta cells...
3.
Tol M, de Bont D, Boon W, de Koning E, van Apeldoorn A
Transpl Int
. 2023 Nov;
36:11077.
PMID: 37908676
Islet delivery devices (IDDs) offer potential benefits for islet transplantation and stem cell-based replacement in type 1 diabetes. Little is known about patient preferences regarding islet delivery device characteristics and...
4.
Sthijns M, Jetten M, Mohammed S, Claessen S, de Vries R, Stell A, et al.
Biomaterials
. 2020 Oct;
267:120449.
PMID: 33129188
The clinical success rate of islet transplantation, namely independence from insulin injections, is limited by factors that lead to graft failure, including inflammation, acute ischemia, acute phase response, and insufficient...
5.
Hadavi E, de Vries R, Smink A, De Haan B, Leijten J, Schwab L, et al.
J Biomed Mater Res B Appl Biomater
. 2020 Jul;
109(1):117-127.
PMID: 32672384
To effectively apply microwell array cell delivery devices their biodegradation rate must be tailored towards their intended use and implantation location. Two microwell array devices with distinct degradation profiles, either...
6.
Smink A, Li S, Swart D, Hertsig D, de Haan B, Kamps J, et al.
J Biomed Mater Res A
. 2017 May;
105(9):2533-2542.
PMID: 28470672
The liver as transplantation site for pancreatic islets is associated with significant loss of islets, which can be prevented by grafting in a prevascularized, subcutaneous scaffold. Supporting vascularization of a...
7.
Smink A, Li S, Hertsig D, de Haan B, Schwab L, van Apeldoorn A, et al.
Transplantation
. 2017 Feb;
101(4):e112-e119.
PMID: 28207637
Background: The liver as transplantation site for human pancreatic islets is a harsh microenvironment for islets and it lacks the ability to retrieve the graft. A retrievable, extrahepatic transplantation site...
8.
Smink A, Hertsig D, Schwab L, van Apeldoorn A, de Koning E, Faas M, et al.
Ann Surg
. 2016 Jul;
266(1):149-157.
PMID: 27429018
Objective: We aim on developing a polymeric ectopic scaffold in a readily accessible site under the skin. Summary Background Data: The liver as transplantation site for pancreatic islets is associated...
9.
Smink A, de Haan B, Paredes-Juarez G, Wolters A, Kuipers J, Giepmans B, et al.
Biomed Mater
. 2016 May;
11(3):035006.
PMID: 27173149
The liver is currently the site for transplantation of islets in humans. This is not optimal for islets, but alternative sites in humans are not available. Polymeric scaffolds in surgically...
10.
Marchioli G, Di Luca A, de Koning E, Engelse M, van Blitterswijk C, Karperien M, et al.
Adv Healthc Mater
. 2016 Apr;
5(13):1606-16.
PMID: 27113576
Although regarded as a promising treatment for type 1 diabetes, clinical islet transplantation in the portal vein is still hindered by a low transplantation outcome. Alternative transplantation sites have been...